Switch theme
Sign up to access all valuation multiples
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gelteq has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Gelteq achieved revenue of n/a and an EBITDA of -$1.7M.
Gelteq expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Gelteq valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.1M | n/a | XXX | XXX | XXX |
| Gross Profit | $0.1M | $31K | XXX | XXX | XXX |
| Gross Margin | 66% | Infinity% | XXX | XXX | XXX |
| EBITDA | -$1.9M | -$1.7M | XXX | XXX | XXX |
| EBITDA Margin | -2350% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$3.4M | -$3.5M | XXX | XXX | XXX |
| Net Margin | -4219% | -Infinity% | XXX | XXX | XXX |
| Net Debt | $1.3M | $2.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Gelteq's stock price is $1.
Gelteq has current market cap of $8.8M, and EV of $11.2M.
See Gelteq trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.2M | $8.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Gelteq has market cap of $8.8M and EV of $11.2M.
Gelteq's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Gelteq's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Gelteq and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $11.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -6.4x | XXX | XXX | XXX |
| P/E | -2.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -9.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGelteq's NTM/LTM revenue growth is n/a
Gelteq's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Gelteq's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Gelteq's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Gelteq and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -7% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanoform | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gelteq acquired XXX companies to date.
Last acquisition by Gelteq was XXXXXXXX, XXXXX XXXXX XXXXXX . Gelteq acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Gelteq founded? | Gelteq was founded in 2018. |
| Where is Gelteq headquartered? | Gelteq is headquartered in United States of America. |
| How many employees does Gelteq have? | As of today, Gelteq has 20 employees. |
| Who is the CEO of Gelteq? | Gelteq's CEO is Mr. Nathan J. Givoni. |
| Is Gelteq publicy listed? | Yes, Gelteq is a public company listed on NAS. |
| What is the stock symbol of Gelteq? | Gelteq trades under GELS ticker. |
| When did Gelteq go public? | Gelteq went public in 2024. |
| Who are competitors of Gelteq? | Similar companies to Gelteq include e.g. LTR Pharma, Starpharma, Schott Pharma, Nanoform. |
| What is the current market cap of Gelteq? | Gelteq's current market cap is $8.8M |
| Is Gelteq profitable? | Yes, Gelteq is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
